

University of Groningen

## Extracellular matrix and (re)myelination

Šišková, Zuzana

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2006

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Šišková, Z. (2006). *Extracellular matrix and (re)myelination*. s.n.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

# **Chapter 5**

---

## **A role for gangliosides in morphological oligodendrocyte differentiation and myelin membrane integrity**

*Zuzana Šišková, Hendrike Maier, Johnny Burema, Dick Hoekstra and Wia Baron*

*Department of Cell Biology, Section Membrane Cell Biology, University Medical Center Groningen, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands*

*manuscript in preparation*

**Abstract**

Studies with transgenic animals lacking complex gangliosides show impaired myelin stability, which has been suggested to be due to disturbed axo-glial interactions. Gangliosides expression in axon appears to be essential, however, a role for gangliosides in the integrity of oligodendrocyte (OLG) derived myelin membranes has not been properly defined yet. Here, we addressed this issue in primary OLGs and an OLG-derived cell line, OLN 93. Pharmacological inhibition of glycosphingolipid (GSL) biosynthesis influenced the stability of OLG membranes, resulting in the formation of extracellular galactosylceramide (GalCer) containing deposits, surrounding OLG cell bodies, which had detrimental consequences on morphological OLG differentiation. Moreover, in GalCer-over expressing OLN 93 cells that lack complex gangliosides similar deposits were formed, as visualized by immunocytochemical and electronmicroscopical analyses. The deposits contained components of the outer leaflet (GalCer), transmembrane spanning proteins (NCAM 140) and  $\beta$ -tubulin cytoskeleton, whereas actin cytoskeleton and components associated with the inner leaflet (CNP) were absent. Additional work indicated that GalCer deposition could be prevented by exogenous administration of the ganglioside GT1b, but not ganglioside GM1. Taken together, the results suggest that a proper ratio of GalCer/ ganglioside (GT1b) needs to be maintained for the formation of stable myelin membranes.

---

## Introduction

Gangliosides are a major class of glycosphingolipids (GSLs) that contain one or more sialic acid residues, and are abundantly present in vertebrate brain (Stults et al., 1989). Thus, it is not surprising that defects in their metabolism could have a most severe impact on this organ. In fact, inherited defects in degradation of gangliosides cause two types of disease in human, i.e., the GM1 and GM2 gangliosidoses (Gravel et al., 1979; Itoh et al., 2001). Furthermore, other genetically determined diseases, not directly related to defects in ganglioside metabolism, such as Niemann-Pick and Gaucher disease, may be associated with a significant accumulation of specific gangliosides (Siegel and Walkley, 1994; Schuchman and Miranda, 1997; Gornati et al., 2002). Differences in ganglioside levels have also been observed in neuroinflammatory pathologies, like the demyelinating disease multiple sclerosis (MS). In MS, the levels of ganglioside GM1, the most abundant ganglioside in myelin (Ueno et al., 1978; Cochran et al., 1982a,b), decreases (Yu et al., 1974), whereas elevated levels of ganglioside GD3 have been reported in the cerebrospinal fluid of MS patients (Miyatani et al., 1990). Likely, activated microglia secrete GD3, which triggers OLG apoptosis (Simons et al., 2002), thus raising the issue as to how gangliosides modulate MS pathology, and remyelination in particular.

However, next to a potentially detrimental role in MS pathology, gangliosides are nevertheless important for myelin stability. For example a role of gangliosides in the maintenance of myelin stability *in vivo* has been suggested by several studies. In *Galgt1*-null mice that fail to express complex brain gangliosides, including GD1a and GT1b, a selective and progressive decrease in expression of myelin-associated glycoprotein (MAG) results in demyelination, and is accompanied by motor behavioral deficits (Sun et al., 2004). Furthermore, the spinal cord of mice lacking complex gangliosides are characterized by disordered myelination and degeneration of nerve fibers (Ma et al., 2003), further suggesting involvement of brain gangliosides in myelin stability. Interestingly, complex ganglioside GT1b mediates axo-glia interactions (Vinson et al., 2001), whereas its level decreases during development of chronic relapsing experimental allergic encephalomyelitis (EAE), an animal model for MS (Zaprianova et al., 1998), and thus might impair remyelination events in MS.

In OLGs, the myelin forming cells of the central nervous system (CNS), the expression of gangliosides is developmentally regulated. In particular, gangliosides (GT3, *O*-acetylated-GT3 and GD2) recognized by the A2B5 antibody (Farrer and Quarles, 1999) and GD3 are present on precursor cells, whereas their expression is lost upon cell differentiation (Levine et al., 1993; Farrer and Quarless, 1999). Furthermore, gangliosides GM1, GM2, GM3, GD1a and GT1b are expressed in OLGs throughout development (Sato et al., 1996), GM1 ganglioside being the major ganglioside in

---

myelin (Ueno et al., 1978; Cochran et al., 1982a,b). The function of developmentally-regulated gangliosides in OLG differentiation is not yet known. However, gangliosides almost exclusively localize to the outer leaflet of the membrane (Hansson et al., 1977), and in other cell types a role in cell adhesion (Blackburn et al., 1986; Probstmeier et al., 1999), process outgrowth (Cannella et al., 1998) and transmembrane signaling by participation in the formation of membrane microdomains (McKerracher, 2002; Sorice et al., 2004) has been reported. These reported functions are important for OLG development as well, and a role for gangliosides in these functions could thus be readily envisioned. Membrane microdomains, for example, have been shown to be important signaling platforms for OLG survival (Baron et al., 2003; Decker and French-Constant, 2004) and myelination (Kramer et al., 1999). Moreover, adhesion of OLG to its target, the axon, is necessary for OLGs to survive *in vivo* (Barres et al., 1993; Barres and Raff, 1999) and an important mediator in this axo-glia adhesion is the axonally-derived extracellular matrix molecule, laminin-2 (Ln2, Colognato et al. 2002). Ln2 also appears to be important in myelin membrane formation (Buttery and French-Constant, 1999; Relvas et al., 2001) and process outgrowth (Šišková et al., submitted (*chapter 4*)). For example, OLG adherence to fibronectin (Fn), which is normally absent in healthy CNS and present under pathological conditions (Sobel and Mitchell, 1989; Šišková et al., *chapter 2*), results in impaired process outgrowth and myelin membrane formation (Buttery and French-Constant, 1999; Maier et al., 2005; Šišková et al., 2006 (*chapter 3*); Šišková et al., submitted (*chapter 4*)).

Taken together, although knowledge about gangliosides structure, metabolism and function gradually emerges, knowledge of how gangliosides control OLG behavior and myelin membrane integrity, is fairly scanty. In the present *in vitro* study, evidence is provided that highlights the importance of ganglioside GT1b in myelin membrane integrity, a prerequisite for myelin compaction. Based on these results, we propose a mechanism, explaining the role of GT1b in myelin stability, which is impaired in complex ganglioside deficient animals.

## Materials and Methods

### Materials

Dulbecco's Modified Eagle's Medium (DMEM), L-glutamine, penicillin/streptomycin and geneticin (G418) were from GIBCO BRL (Life Technologies, Paisley, Scotland). Fetal calf serum (FCS) was obtained from Bodinco (Alkmaar, Netherlands). Paraformaldehyde (PFA) and Triton-X 100 (TX100) were obtained from Merck (Darmstadt, Germany). FGF-2 and PDGF-AA were purchased from Peprotech (Rocky Hill, NJ). Protease inhibitor cocktail tablets (Complete Mini) were obtained from Roche Diagnostic Corp (Mannheim, Germany). DL-threo-1-phenyl-2-palmitoylamino-3-

---

pyrrolidino-1-propanol-HCL (PPPP) and N-butyldeoxynojirimycin-HCL (NBDNJ) were obtained from Biomol international, L.P. (Exeter, UK). Gangliosides GT1b and GM1 were from Alexis Corp. (Läufelfingen, Switzerland). Sep-Pak 18 cartridges were purchased from Waters Corp. (Milford, MA). HRP-conjugated cholera toxin subunit B (CTB) was from EMD biosciences Inc. (La Jolla, CA, USA). HPTLC plates, chloroform and methanol were from Merck (Amsterdam, The Netherlands). All other chemicals were supplied by Sigma Chemical Co. (St. Louis, MO).

#### Antibodies

The R-mAb and O1 hybridoma (Ranscht et al., 1982) were kind gifts of Guus Wolswijk (NIBR, Amsterdam, The Netherlands). Mouse anti-CNPase (IgG1), mouse anti- $\beta$ -tubulin (IgG1) and mouse NCAM 140/180 (IgG2b) were purchased from Sigma Chemical Co. (St. Louis, MO). Rat anti-MBP was obtained from Serotec (Oxford, UK). FITC and TRITC-conjugated antibodies were purchased from Jackson ImmunoResearch (West Grove, Pa., USA).

#### Constructs

The cDNA encoding ceramide galactosyltransferase (*cgt*) was a kind gift of Dr. Brian Popko (Chapel Hill, NC). For cloning, the *cgt* gene was inserted into the *EcoRI* restriction site of the retroviral vector pLXIN (Clontech Biosciences, Mountain View, CA). Recombinant plasmids were grown in TOP10 cells, and plasmids with the cDNA insert in the correct orientation with respect to transcription were identified by restriction analysis. The orientation and the integrity of the obtained pLXIN constructs were confirmed by DNA sequencing. The production of retroviral particles and the subsequent infection and selection of OLN 93 cells were performed according to Maier et al. (2006). An OLN-MOCK and an OLN-G, overexpressing GalCer, were generated. OLN-MOCK was obtained by retroviral infection with vector only (pLXIN). OLN-G is retrovirally infected with the pLXIN-*cgt* and selected for at least 14 days with 2 mg/ml G418. Infection efficiency was in all cases nearly 100%.

#### OLN 93 cultures

The oligodendroglia derived cell line OLN 93, a kind gift of Dr. Christiane Richter-Landsberg (Richter-Landsberg and Heinrich, 1996), were cultured in DMEM supplemented with 10% heat-inactivated FCS, L-glutamine, and the antibiotics penicillin and streptomycin (proliferation medium). Retroviral infection (see above) was performed on passage 28. Cells were trypsinized when they reached near-confluency and experiments were performed with passage 30-38. To test the effect of ECM components, the cells were cultivated on pre-coated poly-L-lysine (PLL, 5  $\mu$ g/ml), laminin-2 (Ln2, 10  $\mu$ g/ml) or fibronectin (Fn, 10  $\mu$ g/ml) tissue culture plastics (Corning

Incorporated Corning, NY). Tissue culture plastics were pre-coated for at least 3 hrs at 37°C. For TLC analysis OLN 93 cells were plated at a density of 500.000 per T75 flask and cultured till 70% confluency in 10% FCS. For immunocytochemical and electronmicroscopical studies cells were grown overnight on Lab-Tek chamber slides (Nalge Nunc) at a density of 4.000 cells per well and grown for at least 3 days in either 10 or 0.5% FCS. To determine the influence of gangliosides on the membrane integrity, 25 µM GT1b or 25 µM GM1 were added directly after attachment of OLN 93 cells to the substrate and kept in culture medium for the duration of the experiment.

#### Primary oligodendrocyte culture

Primary OPCs were obtained from 1-3 day old Wistar rats as described previously (Baron et al., 2002, Maier et al., 2005). Briefly, rats were decapitated, forebrains were collected and a single cell suspension was obtained by mechanical and enzymatic (papain) digestion. Cells were cultured in DMEM, supplemented with 10% FCS, L-glutamine, penicillin and streptomycin for 10-14 days on PLL-coated tissue culture flasks (Nalge Nunc, Naperville, IL). OPCs, growing on top of an astrocyte monolayer, were then isolated by a shake off procedure (McCarthy and de Vellis, 1980). After a 1 hr pre-shake to remove contaminating microglia, flasks were shaken overnight at 240 rpm on an orbital shaker. The floating OPCs obtained by this procedure were further purified by differential adhesion on bacterial culture dishes, to remove astrocytes and microglia. Enriched OPCs were plated on pre-coated dishes (see above) or well chamber slides, and synchronized in SATO medium (Maier et al., 2005), containing PDGF-AA (10 ng/ml) and FGF-2 (10 ng/ml) for 2 days. Differentiation was induced by growth factor withdrawal and cells were grown for 7 days (mature myelinating stage) in SATO medium supplemented with 0,5 % FCS with medium changes twice a week. For immunocytochemical studies, primary OPCs were plated on ECM-precoated 8 well chamber slides at a density of 15.000 cells per well, whereas for GM1 quantification, the cells were plated at the density of 250.000 cells per PLL-precoated 35 mm dish (Nalge Nunc). To inhibit the *de novo* synthesis of gangliosides, 200 µM NBDNJ and 0.5 µM P4 (unless otherwise indicated) were added to the culture medium immediately after initial adhesion and have been re-applied every 72 hrs till the duration of the experiment.

#### Immunohistochemistry

Antibody staining of cell surface components was performed either on live cells at 4°C or on PFA-fixed cells. After blocking aspecific binding with 4% BSA in phosphate buffered saline (PBS) for 10 min, primary OLGs or OLN 93 cells were incubated with R-mAb (1:10; Ranscht et al., 1982) or O1 (1:20) for 30 min, washed three times with PBS and incubated for 25 min with appropriate TRITC or FITC-conjugated secondary antibodies (1:50). After washing with PBS, the nuclei were stained with DAPI. For internal staining, the cells were first gently fixed with 2% PFA in PBS at room temperature (RT) for 20

min, followed by 15 min fixation with 4% PFA. Cells were permeabilized and blocked with 0.1% TX100 and 4% BSA, respectively and subsequently incubated with the appropriate antibody (NCAM 140/180 1:50, CNP 1:100,  $\beta$ -tubulin 1:200) for 60 min in 4% BSA. After washing with PBS, cells were incubated for 30 min at RT with the appropriate fluorescently-conjugated secondary antibodies (FITC- and TRITC-conjugated antibodies 1:50) in combination with DAPI. Actin filament staining on fixed and permeabilized cells was performed with TRITC-labeled phalloidin (1 $\mu$ g/ml, 30 min) as described previously Šišková et al., 2006 (*chapter 3*). For all stainings, mounting medium (1 mg/ml DABCO in 90% glycerol) was added to prevent image fading. The cells were analyzed with a conventional fluorescence microscope (Olympus ProVis AX70) and data were processed using Paint Shop Pro or Adobe Photoshop 7.0 software.

#### Transmission electron microscopy

Cells were fixed with 2% glutaraldehyde in 0.1 M phosphate (pH 7.4) for 20 min at RT. Cells were washed once with 0.1 M phosphate pH 7.4 containing 6.8% sucrose, after which the cells were osmicated with 1% OsO<sub>4</sub> in 0.1 M phosphate for 2 hrs at RT. Cells were dehydrated in a graded series of ethanols (30, 50, 70 and 100% respectively), and embedded in a 1:1 Epon / propylene oxide mixture overnight, followed by embedding in pure Epon. Ultra thin sections were counterstained with uranyl acetate and lead citrate and samples were examined using a Philips CM 100 (FEI electron optics, Eindhoven, The Netherlands).

#### Analysis of cellular glycosphingolipids

Cells were washed three times with PBS and harvested by scraping in 1 ml PBS. Cells were centrifuged at 10.000 rpm at RT, followed by lipid extraction from the cell pellet according to Bligh and Dyer (1959). Briefly, the cell pellet was resuspended in water and sonicated. Total lipid extraction was performed with 3 volumes CHCl<sub>3</sub>/CH<sub>3</sub>OH (2:1, v/v). The chloroform layer was washed once with 1 volume of CH<sub>3</sub>OH/water (1:1, v/v and dried with a nitrogen flow. Phospholipid content was determined according to Böttcher et al. (1961), using phosphate (Pi) as a standard. From equal amounts of phospholipid, acylglycerolipids were hydrolyzed in CHCl<sub>3</sub>/CH<sub>3</sub>OH (1:1, v/v) containing 0.1 M NaOH (0.1M) for 1 hr at 37 °C. The remaining lipids were re-extracted as described above and applied onto high performance thin layer chromatography (HPTLC) plates. Lipids were separated in C<sub>3</sub>H<sub>6</sub>O<sub>2</sub>/CH<sub>3</sub>CH(OH)CH<sub>3</sub>/CHCl<sub>3</sub>/CH<sub>3</sub>OH/25% KCl (25:25:25:10:9, v/v/v/v/v), after which the plates were dried, and sprayed with 10% H<sub>2</sub>SO<sub>4</sub> and 5% CH<sub>3</sub>OH and heated to 120 °C to visualize lipids. Glycosphingolipids were quantified using Scion Image software (Scion Corp., Frederick, MD).

#### Gangliosides extraction

---



Cells were washed three times with PBS and harvested by scraping in 1 ml PBS. Cells were centrifuged at 10,000 rpm at RT, and gangliosides were isolated from cell pellets, as described (Senn et al., 1998). Briefly, cell pellets were extracted in CHCl<sub>3</sub>/CH<sub>3</sub>OH (1:1, v/v) and CHCl<sub>3</sub>/CH<sub>3</sub>OH (2:1, v/v). The supernatants were pooled and dried with a nitrogen flow. Lipids were redissolved and sonicated in CHCl<sub>3</sub>/CH<sub>3</sub>OH (1:1, v/v). After centrifugation and overnight storage at -20°C, the supernatants were collected and dried, and their phospholipid content was determined as described above. Equal amounts of phospholipid were redissolved in diisopropylether-1-butanol (3:2, v/v) by sonication after which 17 mM NaCl was added. The aqueous phase was re-extracted with diisopropylether-1-butanol and subsequently dried. Samples were dissolved in CH<sub>3</sub>OH/water (1:1, v/v) and loaded onto prewashed Sep-Pak C18 cartridges. After washing with water, gangliosides were eluted with CH<sub>3</sub>OH followed by CHCl<sub>3</sub>/CH<sub>3</sub>OH (1:1, v/v). The eluate was concentrated by drying and loaded onto HPTLC plates. Gangliosides were separated in CHCl<sub>3</sub>/CH<sub>3</sub>OH/0.2% (w/v) CaCl<sub>2</sub> (11:9:2, v/v/v). Dried plates were sprayed with Ehrlich reagent, covered with a glass plate and heated to 180°C. Gangliosides were quantified using Scion Image software (Scion Corp., Frederick, MD).


#### GM1 quantification (dot blot)

The cells were washed three times with PBS and harvested by scraping into 1 ml PBS. Cells were centrifuged at 10,000 rpm at RT and pellets were lysed in TNE-lysis buffer (50mM Tris-HCL, 5mM EDTA, 150 mM NaCl, 1% Triton X-100 and protease inhibitor cocktail). Protein determination was performed by a Bio-Rad DC Protein Assay (Bio-Rad Laboratories, Hercules, CA), using BSA as a standard. Equal amounts of protein in equal volumes (max. 10 µl) were applied onto nitrocellulose membrane. When dried, membranes were incubated for 1 hr at RT in blocking solution (5% nonfat dry milk in PBS). After washing, the membranes were incubated for 2 hrs with HRP-conjugated in 1% nonfat dry milk in PBS containing 0.1% Tween 20. The membranes were washed three times with PBS containing 0.1% Tween 20. Signals were detected by enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech), scanned and processed using Paint Shop Pro and quantified with Scion Image software (Scion Corp., Frederick, MD).

## Results

### **Glycosphingolipid characterization of primary rat oligodendrocytes and OLN 93 cells**

In previous studies we and others have shown that ECM molecules play an important role in myelin membrane formation (Buttery and French-Constant, 1999; Maier et al., 2005; Šišková et al., 2006 (*chapter 3*)). Whereas Ln2 is beneficial, Fn severely retards morphological OLG differentiation, and therefore myelin formation (Maier et al., 2005; Šišková et al., submitted (*chapter 4*)). As laminin is able to upregulate ganglioside synthesis in primary Schwann cells (Farrer and Quarles, 1996), the myelinating cells of the PNS, a role of gangliosides in ECM-dependent myelination could be anticipated.



**Figure 1. Glycosphingolipid expression in primary OLGs and OLN 93 cells on different extracellular matrix molecules.** Primary OLGs (A, B) and OLN 93 (C, D, 10% FCS) cells were cultured on laminin-2, fibronectin or poly-L-lysine for 7 days and 3 days respectively, after which neutral glycosphingolipids (A, C) and ganglioside (acidic glycosphingolipids, B, D) expression was analyzed as described in Materials and Methods. Representative TLCs of at least 3 independent experiments are shown. Note, the slight increase in the general expression of gangliosides, and GM3, GM1, GD3 and GT1b in particular, on laminin-2 as compared to poly-L-lysine and fibronectin in primary OLGs. In OLN 93 cells only ganglioside GM3 is expressed in detectable levels.



Therefore, we examined ganglioside expression in mature myelinating OLGs, cultured on different ECM substrates, i.e. inert poly-L-lysine (PLL), Fn and Ln2. In parallel, the expression of the galactosphingolipids, galactosyl ceramide (GalCer) and its sulfated derivative, sulfatide, were analyzed, both of which are abundant in primary OLGs (Menon et al., 2003) and important for OLG maturation (Pfeiffer et al., 1993; Bansal et al., 1999; Hirahara et al., 2004). As shown in figure 1A, in primary OLGs major ECM-mediated differences in glycosphingolipid (GSL) expression were not observed. In contrast, ganglioside expression (GM3, GM1, GD3 and GT1b) on Ln2 as compared to PLL and Fn was slightly increased. (fig.1B). Next, we determined the GSL profiles in OLN 93 cells, previously shown to express similar properties in terms of trafficking of myelin proteins and cell differentiation as primary OLGs, when grown on different ECM substrates (Šišková et al., 2006 (*chapter 3*); Šišková et al., submitted (*chapter 4*)). As shown in figure 1C, proliferating OLN 93 express on all substrates similar levels of glucosylceramide (GlcCer), ceramide and the phospholipid sphingomyelin (SM), and hardly, if at all, the myelin typical lipids GalCer or sulfatide. Interestingly, on Ln2 and Fn additional yet unidentified lipids appeared. Intriguingly, however, ganglioside GM3 is the only detectable ganglioside in OLN 93, implying that these cells are completely lacking structurally more complex gangliosides (fig. 1D). Again, no quantitative effect on the extent of GM3 was seen when the cells were grown on different substrates. Hence, these data suggested that ECM molecules hardly, if at all, modulate glycosphingolipid expression in OLGs. To assess if gangliosides are involved in myelin membrane formation per se, we next examined, if OLG development is ganglioside-dependent.

***Inhibition of glycosphingolipid biosynthesis impedes primary process extension in OLGs and gives rise to GalCer positive extracellular deposits***

In order to reveal a role for gangliosides in OLG maturation *in vitro*, *de novo* biosynthesis of GSL was inhibited using pharmacological inhibitors. GlcCer synthase catalyzes the transfer of glucose of UDP-glucose to ceramide to form GlcCer, which is the common precursor of high-order glucosylceramide-based, GSL, including gangliosides. N-butyldeoxynojirijmycin (NBDNJ) inhibits both ceramide-specific glucosyltransferase and  $\alpha$ -glucosidases and is a potent and non-cytotoxic inhibitor of GlcCer synthesis *in vitro* (Platt et al., 1998). DL-threo-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol-HCL (PPPP) is another specific inhibitor of GlcCer synthase, thereby also inhibiting ganglioside synthesis, without significantly affecting intracellular levels of ceramide (Lee et al., 1999), GalCer and sulfatide (our unpublished observations). These inhibitors were added to OPCs, i.e. before the onset of myelin sheet formation. Furthermore, their effect was analyzed on all substrates, but only the results on the inert PLL substrate are shown, as virtually identical results were obtained on all ECMs examined. Given the limited amount of cells available, and hence the need

for microanalysis of the lipid pools we improved the sensitivity of lipid detection, a dot blot assay was applied.

A




**Figure 2. Localization of GalCer in primary OLGs upon inhibition glucosylceramide synthesis.** Primary OPCs were plated on poly-L-lysine, allowed to adhere, after which, NBDNJ and P4 at the indicated concentrations were added. These glucosylceramide synthesis inhibitors were continuously present in the culture medium. The cells were grown for 7 days, after which GM1 expression was determined (A) and GalCer distribution visualized (B-D) with immunofluorescence as described in Materials and Methods. A) cellular GM1 expression as quantified with a dotblot. Note, the dose-dependent decrease in GM1 expression by both inhibitors. A representative experiment out of two is shown. B) GalCer distribution in control cells, C) GalCer distribution in PPPP (0.5  $\mu$ M)-treated cells, D) GalCer distribution in NBDNJ (200  $\mu$ M)-treated cells. Representative pictures of at least 3 independent experiments are shown. Scale bar is 2  $\mu$ m. Note that inhibition of glucosylceramide synthesis by both inhibitors (C, D) prevented morphological differentiation of OLG, and induced extracellular deposition of GalCer.

Figure 2A shows a dose-dependent inhibition of GM1 expression with both inhibitors, and for further experiments, 0.5  $\mu$ M PPPP (80-85 % inhibition) and 200  $\mu$ M NBDNJ (65-70 % inhibition) were used. Whereas in control cells a highly branched GalCer positive network of processes extending from the cell body was formed (fig. 2B), in cells in which GlcCer biosynthesis was inhibited, process formation was impeded and extracellular deposits containing GalCer appeared, closely surrounding cell bodies. Inhibition of morphological differentiation and GalCer positive extracellular deposits were observed with both inhibitors (PPPP, fig. 2C, NBDNJ, fig. 2D). Hence, these data suggest that GlcCer synthesis is essential for morphological OLG differentiation. To assess if the depositing of GalCer-containing membrane structures was due to the absence of *de*

*novo* GlcCer biosynthesis *per se*, or due to the absence of a GlcCer-based GSL, such as gangliosides, we next examined whether OLN 93 cells, which lack complex gangliosides and only express ganglioside GM3 (fig. 1D), could also form similar deposits.

### ***GalCer-expressing OLN-G cells, but not OLN-MOCK cells, form extracellular deposits***

In order to investigate the relation between a particular GlcCer-based GSL and deposition of GalCer positive extracellular membrane structures, we examined GalCer deposition in OLN 93 cells that only express the relatively simple ganglioside GM3 (fig.1D). As they also express rather low GalCer levels (fig.1C), we first retrovirally overexpressed galactosyl ceramide transferase (*cgt*) to improve GalCer biosynthesis in OLN 93 cells, hereafter referred to as OLN-G. As compared to control mock transfected cells (MOCK; fig. 3A, line 1), infected OLN-G cells significantly overexpress GalCer (fig. 3A). A double band is visible, representing non-hydroxylated (upper band) and hydroxylated (lower band) GalCer. In addition, low but detectable levels of sulfatide were seen in OLN-G cells, however these levels were too low for immunofluorescent detection.



**Figure 3. GalCer localization in GalCer-overexpressing OLN 93 cells.** OLN-MOCK (D) and GalCer-overexpressing OLN-G cells (B, C, E) were generated as described in Materials and Methods. Cells were cultured on poly-L-lysine for 3 days (B, C) or 24 hrs (D, E) in either 10% (B) or 0.5% FCS (C-E) and GalCer distribution (B, C) and membrane integrity using transmission electronmicroscopy (D, E) were analyzed as described in Materials and Methods. A) Neutral glycosphingolipid expression in OLN-MOCK and OLN-G cells. Note that GalCer is significantly overexpressed in OLN-G as compared to OLN-MOCK. B) GalCer distribution in OLN-G cells, 10% FCS, C) GalCer distribution in OLN-G cells, 0.5% FCS. Representative pictures out of at

least 3 independent pictures are shown. Scale bar is 2  $\mu\text{m}$ . Note, that as in primary cells, GalCer-positive deposits are formed (arrows). D) OLN-MOCK, 0.5% FCS, E) OLN-G, 0.5% FCS. Representative images out of at least 3 independent experiments are shown. Note that the membrane integrity is severely impeded in OLN-G cells as compared to OLN-MOCK cells, indicating that GalCer expression is essential for extracellular deposit formation. Scale bar is 10  $\mu\text{m}$ .


Remarkably, the OLN-G cells were in general more spread and fewer processes were formed (data not shown). Interestingly, however, the OLN-G cells spontaneously formed GalCer-positive extracellular deposits surrounding the cell body (fig. 3B), similarly as observed for primary OLGs, except that in these cells the effect was only seen upon inhibition of GlcCer biosynthesis. Furthermore, GalCer deposition was even more prominent upon serum withdrawal, i.e. upon triggering differentiation of the cells (fig. 3C). Importantly, as in OLN 93 cells, only ganglioside GM3 is expressed in OLN-MOCK and OLN-G cells (data not shown). Intriguingly, as examined with transmission electron microscopy (TEM), in OLN-G cells substantial degeneration of the plasma membrane was observed, as evidenced by secreted membranous structures (fig. 3E). These secreted membrane-like structures were not detectable in OLN-MOCK cells (fig. 3D) that express relatively low levels of GalCer (fig. 3A), thus suggesting that a relative excess of GalCer, artificially induced in control cells in which overall GSL biosynthesis is impaired, is instrumental in the formation of these deposits.

#### ***Extracellular deposits in OLN-G cells contain membrane proteins and cytoskeletal components***


To further analyze the composition of the extracellular deposits formed in OLN-G cells, the distribution of several plasma membrane proteins at the cell surface was compared in control cells and OLN-G cells, using immunofluorescence. Whereas in OLN-MOCK, the distribution of the transmembrane spanning protein NCAM 140 randomly localized to the plasma membrane (fig. 4A), in OLN-G cells, NCAM 140 is not associated with the cell boundaries (fig. 4B) but co-localized with the GalCer positive deposits (fig. 4D). In contrast, CNP, known to be associated with the inner leaflet of the plasma membrane only (Braun et al., 1991) is similarly distributed in OLN-G (fig. 4F) as in OLN-MOCK (fig. 4E) cells, i.e. very little if any colocalisation (fig. 4H) with the GalCer positive deposits (fig. 4G). As process formation was severely impeded both upon inhibition of GlcCer synthesis in primary OLGs and in OLN-G cells, we next analyzed the localization of the cytoskeletal proteins actin and  $\beta$ -tubulin. The distribution of the actin cytoskeleton, as visualized with phalloidin-TRITC, is similar in OLN-MOCK (fig. 4I) and OLN-G (fig. 4J), and no colocalisation of actin with extracellular deposits was detected (fig. 4J-L). In contrast,  $\beta$ -tubulin, known to be primarily present in primary processes of OLGs (Wilson and Brophy, 1989), colocalised with the extracellular deposits in OLN-G (fig. 4N-P), whereas in OLN-MOCK the  $\beta$ -tubulin distribution is confined to the cells (fig. 4M).



Therefore, these data suggest that the plasma membrane of OLN-G cells is severely disorganized, with a concomitant membrane destabilization, which apparently resulted in the extracellular deposition of outer leaflet membrane components (GalCer), transmembrane spanning components (NCAM 140) and  $\beta$ -tubulin, whereas the actin cytoskeleton, and inner leaflet associated proteins (CNP) remained cell-associated. Intriguingly, in spite of this apparent perturbation, OLN-G cells are still capable to grow and proliferate. As similar deposits were observed in primary OLGs in which overall GlcCer biosynthesis had been inhibited, and spontaneously in OLN-G cells, that overexpress GalCer and only express GM3 as the sole ganglioside, we next examined whether a complex ganglioside might be involved in affecting OLG membrane integrity.



**Figure 4. Immunofluorescent characterisation of extracellular deposit content.** OLN-MOCK (A, E, I, M) and OLN-G cells (B-D, F-H, J-L, N-P) were cultured for 3 days on poly-L-lysine in 0.5% cells were immunolabeled against NCAM 140 (A, B), CNP (E, F) and  $\beta$ -tubulin (M, N). Actin filaments (I, J) were visualized with TRITC-labelled phalloidin. Representative pictures of at least 3 independent experiments are shown. Scale bar is 2  $\mu$ m. In OLN-G cells deposits were visualized with O1, an anti-GalCer antibody (C, G, K, O), and co-localisation with the indicated components is visualized in the overlay images (D, H, L, P). Note, that NCAM 140 and  $\beta$ -tubulin were part of the extracellular deposits, whereas CNP and actin remained cell-associated.

**Exogenous addition of GT1b counteracts the formation of extracellular deposits**

**Figure 5. Effect of exogenous ganglioside addition on extracellular deposit formation in OLN-G cells.** OLN-G cells were plated on poly-L-lysine, allowed to adhere, after which, 25  $\mu$ M GT1b (A, C) or 25  $\mu$ M GM1 (B, D) were added, after which the cells were cultured for 3 days in 0.5% FCS and GalCer distribution (A, B) and membrane integrity (C, D) analyzed as described in Materials and Methods. A) GalCer distribution upon GT1b addition, B) GalCer distribution upon GM1 addition. Representative pictures out of at least 3 independent experiments are shown. Scale bar is 2  $\mu$ m. Note that, in contrast to GM1 addition (B, arrow), GT1b addition (A) prevented extracellular deposit formation, and allowed GalCer incorporation in the plasma membrane (arrowhead). C) representative TEM picture upon GT1b addition, D) representative TEM picture upon GM1 addition. Note that GT1b but not GM1 addition increased membrane integrity in OLN-G cells. Scale bar is 5  $\mu$ m.

To examine whether complex gangliosides might be involved in modulating myelin membrane integrity, we next determined if exogenous administration of gangliosides could prevent GalCer deposit formation. Indeed, exogenously added gangliosides have been shown to readily insert into the plasma membrane, participating in ganglioside metabolism and cellular signalling (Keenan et al., 1974; Fishman et al., 1977; Masco et al., 1989; Leskawa et al., 1989). Figure 5 shows that addition of structurally complex ganglioside GT1b to OLN-G cells resulted in GalCer positive plasma membranes, i.e., marking a clear membrane boundary without extensive deposit formation or membrane ruffling (fig 5A). Hence, these data suggested that membrane inserted GT1b stabilized the membrane structure. The effect of GT1b appears to be specific, as upon addition of ganglioside GM1, deposit formation in OLN-G cells was not inhibited (fig. 5B), showing a membrane ruffling as in OLN-G control cells (fig. 2). These immunofluorescence data were confirmed with TEM. Thus, addition of GT1b (fig. 5C) to OLN-G cells resulted in a significant diminishment of membrane disruption, in contrast to addition of GM1 (fig. 5D), which was essentially without effect. Administration of GT1b or GM1 had no effect on



the morphology and membrane integrity of OLN-MOCK cells (data not shown). Taken together these data suggest an important role for complex ganglioside GT1b, in membrane integrity, possibly by harbouring excess amounts of GalCer synthesized upon OLG differentiation.

## Discussion

In the present study we show that modulation of the level of the GSL GalCer, relative to that of other GSLs, either by its overexpression per se (in OLN cells) or upon inhibition of GlcCer biosynthesis, which also blocks complex ganglioside biosynthesis but not that of GalCer, destabilizes the membrane structure of OLG, the myelinating cells in brain. The severe degeneration of the membrane is evidenced by extracellular deposition of GalCer-positive membranous structures surrounding the cell body. Since exogenous addition of the ganglioside GT1b counteracts this disintegration the data might support the notion that a perturbation of GSL homeostasis is detrimental for OLG membrane stability and hence myelin assembly and stability. The data might thus suggest a role for complex gangliosides in adjusting the lateral membrane environment to harbour high GalCer levels. Indeed, excess GalCer, as induced in overexpressing OLN-G cells is adequately sequestered within the membrane without extensive disruption upon exogenous addition of GT1b, but not GM1. Hence, these data suggest potential specificity of a role for particular gangliosides in controlling myelin membrane integrity, allowing morphological OLG differentiation and process extension in particular. Consistent with this notion, myelination defects are observed in transgenic mice lacking complex gangliosides (Sheikh et al., 1999; Kawai et al., 2001; Ma et al., 2003, Yasmashita et al., 2005). Furthermore, ganglioside synthesis and expression in axons is essential for proper axon to glia communication (Vinson et al., 2001; Vyas and Schnaar, 2001). Myelin-associated glycoprotein (MAG) localised in the myelin membrane adjacent to the axon, is a ligand for neuronal GD1a and GT1b (Yang et al., 1996, Vinson et al., 2001; Vyas and Schnaar, 2001; Vyas et al., 2002), and this interaction stabilizes axon-myelin interactions (Sun et al., 2004). However, the data in the present study indicate that for stabilization of the myelin membrane, ganglioside expression, and possibly GT1b in particular, in OLGs is essential as well. Thus our findings that membrane integrity appears to be highly dependent on a proper ratio of GalCer and complex gangliosides, could provide an indication for possible cellular mechanisms underlying the disordered myelination observed in all transgenic animals, lacking complex gangliosides, and hence expressing a relative excess of GalCer. The observation that the phenotypes of GalCer-deficient or complex ganglioside-deficient mice are very similar, i.e., in both cases reflecting a perturbation in GalCer/Ganglioside

---

ratio, is in support of this (Coetzee et al., 1996; Honke et al., 2002; Yamashita et al., 2005).

The present study showed also an impaired morphological differentiation of primary OLG progenitors upon inhibition of GlcCer synthesis. Strikingly, process outgrowth was severely impeded, and primary processes were hardly, if at all, observed, suggesting that gangliosides may play a functional role in this process. Indeed, exogenous addition of ganglioside GM3 stimulates process outgrowth by cultured bovine OLGs, resulting in process elongation and extensive process branching (Yim et al., 1991, 1994). Similarly, exogenously administered gangliosides to primary neurons in vitro stimulates neurite sprouting and extension (Roisen et al., 1981; Ledeen, 1984; Skaper et al., 1985), and accumulation of gangliosides within neurons in ganglioside storage diseases results in extensive neurite outgrowth (Purpura, 1987). Extensive cytoskeletal remodelling is needed for process sprouting and extension, and in OLGs microtubules are specifically present in primary processes (Wilson and Brophy, 1989). In this respect, our finding that  $\beta$ -tubulin, but not actin, is present in the extracellular deposits, corroborates the notion that in the absence of complex gangliosides and high GalCer levels, primary process formation is deregulated. Whether ganglioside GT1b is involved in primary process formation remains to be determined, however, since GT1b in OLGs is specifically localized to the cell body and in a patchy appearance at branching points (Schnaar et al., 1996), such a role could be readily foreseen.

Gangliosides reside in the outer leaflet of the plasma membrane and there is ample evidence (Ledeen, 1985; Thomas and Brewer, 1990; Yim et al., 1991; Probstmeier et al., 1999) that next to a structural function, gangliosides have a role as active signaling partners, especially in regulating cellular interactions. For example, gangliosides may participate in the organization of the membrane by directing adhesion receptors to discrete areas. Indeed, the function of integrins, the main receptors of ECM molecules, are affected by endogenous metabolism and exogenous addition of gangliosides (Ono et al., 2001; Satoh et al., 2001). In OLGs, ganglioside-mediated signaling regulates integrin-mediated adhesion of OLGs progenitors to the ECM molecule tenascin-R (Probstmeier et al., 1999). Intriguingly, previous studies (Matyas et al., 1986) and our preliminary experiments suggest that fibronectin binds to ganglioside GT1b, which could explain the hampered process formation and myelination on fibronectin (Buttery and French-Constant, 1999; Maier et al., 2005; Šišková et al., 2006 (*chapter 3*); Šišková et al., submitted (*chapter 4*), i.e. fibronectin-mediated adhesion to ganglioside GT1b could preclude its role in morphological OLG differentiation. Therefore, ganglioside GT1b-ECM interactions may contribute to OLG myelination.

Interestingly, in an MS animal model, chronic relapsing experimental allergic encephalomyelitis, GM1 levels increase and GT1b levels decrease, suggesting a role for gangliosides in autoimmune demyelination (Zaprianova et al., 1998). Indeed, numerous

---

studies have focused on the involvement of gangliosides in autoimmune demyelinating diseases (Rapport and Huang, 1985; Schwerer et al., 1986; Stevens et al., 1992). In fact, an MS-like disease develops in rabbits upon immunization with brain gangliosides (Cohen et al., 1981). Moreover, antisera against GM1, GD1a, GD1b and GT1b induce demyelination in spinal cord and spinal roots (Schwerer et al., 1986). Intriguingly, the cellular mechanisms underlying gangliosides-induced demyelination are unknown. However, with the proposed role of complex gangliosides in OLG membrane integrity, it is very well possible that modulation of ganglioside levels disturbs the organization of myelin membranes, resulting in extracellular GalCer deposition, and leading to demyelination. These considerations justify further detailed work on the role of glycosphingolipids in determining myelin membrane stability, in particular in the context of a search for novel targets in treatment of demyelinating diseases.

### Acknowledgments

We would like to thank to Karin Klappe for help and advice with glycosphingolipid extractions. Ietse Stokroos, Ruby Kalicharan and Bert Blaauw are acknowledged for help with transmission electron microscopy. Adam Klimiuk is acknowledged for performing some lipid analysis. We thank all people in Dick Hoekstra's lab for inspiring discussion and help. Z.S. is a recipient of PhD fellowship from the Graduate School of Behavioral and Cognitive Neurosciences, University of Groningen, The Netherlands. This work was supported by grants from the Dutch Foundation for the Support of MS Research 'Stichting MS Research' to W.B. and the Foundation "De Drie Lichten" in The Netherlands to Z.S.

### References

- Bansal R, Winkler S, Bheddah S. 1999. Negative regulation of oligodendrocyte differentiation by galactosphingolipids. *J Biol Chem* 274:7913-24.
- Baron W, Decker L, Cognato H, French-Constant C. 2003. Regulation of integrin growth factor interactions in oligodendrocytes by lipid raft microdomains. *Curr Biol* 13:151-5.
- Barres BA, Jacobson MD, Schmid R, Sendtner M, Raff MC. 1993. Does oligodendrocyte survival depend on axons? *Curr Biol* 3: 489-97.
- Barres BA, Raff MC. 1999. Axonal control of oligodendrocyte development. *J Cell Biol* 147:1123-8.
- Blackburn CC, Swank-Hill P, Schnaar RL. 1986. Gangliosides support neural retina cell adhesion. *J Biol Chem* 261:2873-81.
- Bligh EJ, Dyer WJ. 1959. A rapid method of total lipid extraction and purification. *Can J Biochem Physiol* 37:911-7.
- Böttcher CJF, van Gent CM, Pries C. 1961. A rapid and sensitive submicro phosphorus determination. *Anal Chim Acta* 24: 203-4.
- Braun PE, De Angelis D, Shtybel WW, Bernier L. 1991. Isoprenoid modification permits 2',3'-cyclic nucleotide 3'-phosphodiesterase to bind to membranes. *J Neurosci Res* 30:540-4.
-

- Buttery PC, French-Constant C. 1999. Laminin-2/integrin interactions enhance myelin membrane formation by oligodendrocytes. *Mol Cell Neurosci* 3:199-212.
- Cannella MS, Acher AJ, Ledeen RW. 1988. Stimulation of neurite outgrowth in vitro by a glycerol-ganglioside. *Int J Dev Neurosci* 6:319-26.
- Cochran FB Jr, Yu RK, Ledeen RW. 1982a. Myelin gangliosides in vertebrates. *J Neurochem* 39:773-9.
- Cochran FB, Ledeen RW, Yu RK. 1982b. Gangliosides and proteins in developing chicken brain myelin. *Brain Res* 282:27-32.
- Cohen O, Sela BA, Schwartz M, Eshhar N, Cohen IR. 1981. Multiple sclerosis-like disease induced in rabbits by immunization with brain gangliosides. *Isr J Med Sci* 17:711-4.
- Colognato H, Baron W, Avellana-Adalid V, Relvas JB, Baron-Van Evercooren A, Georges-Labouesse E, French-Constant C. 2002. CNS integrins switch growth factor signalling to promote target-dependent survival. *Nat Cell Biol* 4:833-41.
- Colognato H, French-Constant C, Feltri ML. 2005. Human diseases reveal novel roles for neural laminins. *Trends Neurosci* 28:480-6.
- Colombaioni L, Garcia-Gil M. 2004. Sphingolipid metabolites in neural signalling and function. *Brain Res Brain Res Rev* 46:328-55.
- Coetzee T, Fujita N, Dupree J, Shi R, Blight A, Suzuki K, Suzuki K, Popko B. 1996. Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. *Cell* 86:209-19.
- Decker L, French-Constant C. 2004. Lipid rafts and integrin activation regulate oligodendrocyte survival. *J Neurosci* 24:3816-25.
- Farrer RG, Quarles RH. 1996. Extracellular matrix upregulates synthesis of glucosylceramide-based glycosphingolipids in primary Schwann cells. *J Neurosci Res* 45:248-57.
- Fishman PH, Moss J, Manganiello VC. 1977. Synthesis and uptake of gangliosides by cholera-responsive human fibroblasts. *Biochemistry* 16:1871-5.
- Gornati R, Berra B, Montorfano G, Martini C, Ciana G, Ferrari P, Romano M, Bembi B. 2002. Glycolipid analysis of different tissues and cerebrospinal fluid in type II Gaucher disease. *J Inher Metab Dis* 25:47-55.
- Gravel RA, Lowden JA, Callahan JW, Wolfe LS, Ng Yin Kin NM. 1979. Infantile sialidosis: a phenocopy of type 1 GM1 gangliosidosis distinguished by genetic complementation and urinary oligosaccharides. *Am J Hum Genet* 31:669-79.
- Hakomori S. 2003. Structure, organization, and function of glycosphingolipids in membrane. *Curr Opin Hematol* 10:16-24.
- Hansson HA, Holmgren J, Svennerholm L. 1977. Ultrastructural localization of cell membrane GM1 ganglioside by cholera toxin. *Proc Natl Acad Sci U S A* 74:3782-6.
- Hirahara Y, Bansal R, Honke K, Ikenaka K, Wada Y. 2004. Sulfatide is a negative regulator of oligodendrocyte differentiation: development in sulfatide-null mice. *Glia* 45:269-77.
- Honke K, Hirahara Y, Dupree J, Suzuki K, Popko B, Fukushima K, Fukushima J, Nagasawa T, Yoshida N, Wada Y, Taniguchi N. 2002. Paranodal junction formation and spermatogenesis require sulfoglycolipids. *Proc Natl Acad Sci U S A* 99:4227-32.
- Itoh M, Matsuda J, Suzuki O, Ogura A, Oshima A, Tai T, Suzuki Y, Takashima S. 2001. Development of lysosomal storage in mice with targeted disruption of the beta-galactosidase gene: a model of human G(M1)-gangliosidosis. *Brain Dev* 23:379-84.
- Kawai H, Allende ML, Wada R, Kono M, Sango K, Deng C, Miyakawa T, Crawley JN, Werth N, Bierfreund U, Sandhoff K, Proia RL. 2001. Mice expressing only monosialoganglioside GM3 exhibit lethal audiogenic seizures. *J Biol Chem* 276:6885-8.
- Kawai K, Kuroda S, Watarai S, Takahashi H. 1994. Developmental profile of ganglioside GD3 in the central nervous system: an immunocytochemical study in the rat. *Neurosci Res* 21:77-82.
- Keenan TW, Morre DJ, Basu S. 1974. Ganglioside biosynthesis. Concentration of glycosphingolipid glycosyltransferases in Golgi apparatus from rat liver. *J Biol Chem* 249:310-5.
- Kramer EM, Klein C, Koch T, Boytchin M, Trotter J. 1999. Compartmentation of Fyn kinase with glycosylphosphatidylinositol-anchored molecules in oligodendrocytes facilitates kinase activation during myelination. *J Biol Chem* 274:29042-9.
- Ledeen RW. 1984. Biology of gangliosides: neuritogenic and neuronotrophic properties. *J Neurosci Res* 12:147-59.
- Lee L, Abe A, Shayman JA. 1999. Improved inhibitors of glucosylceramide synthase. *J Biol Chem* 274: 14662-9.
- Leskawa KC, Erwin RE, Leon A, Toffano G, Hogan EL. 1989. Incorporation of exogenous ganglioside GM1 into neuroblastoma membranes: inhibition by calcium ion and dependence upon membrane protein. *Neurochem Res* 14:547-54.

- Levine JM, Stincone F, Lee YS. 1993. Development and differentiation of glial precursor cells in the rat cerebellum. *Glia*. 7:307-21.
- Ma Q, Kobayashi M, Sugiura M, Ozaki N, Nishio K, Shiraishi Y, Furukawa K, Furukawa K, Sugiura Y. 2003. Morphological study of disordered myelination and the degeneration of nerve fibers in the spinal cord of mice lacking complex gangliosides. *Arch Histol Cytol*. 66:37-44.
- Maier O, van der Heide T, van Dam AM, Baron W, de Vries H, Hoekstra D. 2005. Alteration of the extracellular matrix interferes with raft association of neurofascin in oligodendrocytes. Potential significance for multiple sclerosis? *Mol Cell Neurosci*. 28:390-401.
- Maier O, van der Heide T, Johnson R, de Vries H, Baron W, Hoekstra D. 2006. The function of neurofascin155 in oligodendrocytes is regulated by metalloprotease-mediated cleavage and ectodomain shedding. *Exp Cell Res*. 312:500-11.
- Masco D, Flott B, Seifert W. 1989. Astrocytes in cell culture incorporate GM1 ganglioside. *Glia*. 2:231-40.
- Matyas GR, Evers DC, Radinsky R, Morre DJ. 1986. Fibronectin binding to gangliosides and rat liver plasma membranes. *Exp Cell Res* 162: 296-318.
- McCarthy KD, de Vellis J. 1980. Preparation of separate and oligodendroglial cell cultures from rat cerebral tissue. *J Cell Biol*. 85:890-902.
- McKerracher L. 2002. Ganglioside rafts as MAG receptors that mediate blockade of axon growth. *Proc Natl Acad Sci U S A*. 99:7811-3.
- Mendez-Otero R, Santiago MF. 2003. Functional role of a specific ganglioside in neuronal migration and neurite outgrowth. *Braz J Med Biol Res*. 36:1003-13.
- Menon K, Rasband MN, Taylor CM, Brophy P, Bansal R, Pfeiffer SE. 2003. The myelin-axolemmal complex: biochemical dissection and the role of galactosphingolipids. *J Neurochem*. 87:995-1009.
- Miyatani N, Saito M, Ariga T, Yoshino H, Yu RK. 1990. Glycosphingolipids in the cerebrospinal fluid of patients with multiple sclerosis. *Mol Chem Neuropathol*. 13:205-16.
- Molander M, Berthold CH, Persson H, Fredman P. 2000. Immunostaining of ganglioside GD1b, GD3 and GM1 in rat cerebellum: cellular layer and cell type specific associations. *J Neurosci Res*. 60:531-42.
- Ono M, Handa K, Sonnino S, Withers DA, Nagai H, Hakomori S. 2001. GM3 ganglioside inhibits CD9-facilitated haptotactic cell motility: coexpression of GM3 and CD9 is essential in the downregulation of tumor cell motility and malignancy. *Biochemistry*. 40:6414-21.
- Pfeiffer SE, Warrington AE, Bansal R. 1993. The oligodendrocyte and its many cellular processes. *Trends Cell Biol*. 3:191-7.
- Platt FM. 1997. Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin. *J Biol Chem* 272: 19365-19372.
- Platt F.M. and Butters T.D. 1998. New therapeutic prospects for the glycosphingolipid lysosomal storage diseases. *Biochem Pharmacol* 56: 421-430.
- Probstmeier R, Michels M, Franz T, Chan BM, Pesheva P. 1999. Tenascin-R interferes with integrin-dependent oligodendrocyte precursor cell adhesion by a ganglioside-mediated signalling mechanism. *Eur J Neurosci*. 11:2474-88.
- Purpura, DP. 1978. Ectopic dendritic growth in mature pyramidal neurones in human ganglioside storage disease. *Nature* 276:520-521.
- Ranscht B, Clapshaw PA, Price J, Noble M, Seifert W. 1982. Development of oligodendrocytes and Schwann cells studied with a monoclonal antibody against galactocerebroside. *Proc Natl Acad Sci U S A*. 79:2709-13.
- Rapport MM, Huang Y. 1984. Present status of the immunology of gangliosides. *Adv Exp Med Biol*. 174:15-25.
- Relvas JB, Setzu A, Baron W, Buttery PC, LaFlamme SE, Franklin RJ, French-Constant C. 2001. Expression of dominant-negative and chimeric subunits reveals an essential role for beta1 integrin during myelination. *Curr Biol*. 11:1039-43.
- Richter-Landsberg C, Heinrich M. 1996. OLN-93: a new permanent oligodendroglia cell line derived from primary rat brain glial cultures. *J Neurosci Res*. 45:161-73.
- Roisen FJ, Bartfeld H, Nagele R, Yorke G. 1981. Ganglioside stimulation of axonal sprouting in vitro. *Science* 214, 577-578
- Satoh JI, Tai T, Kim SU. 1996. Differential expression of gangliosides and galactolipids in fetal human oligodendrocytes and astrocytes in culture. *Brain Res Dev Brain Res*. 93:172-81.
- Satoh M, Ito A, Nojiri H, Handa K, Numahata K, Ohyama C, Saito S, Hoshi S, Hakomori SI. 2001. Enhanced GM3 expression, associated with decreased invasiveness, is induced by brefeldin A in bladder cancer cells. *Int J Oncol*. 19:723-31.
-

- Schnaar RL, Longo P, Yang LJS, Tai T. 1996. Distinctive ganglioside patterns revealed by anti-ganglioside antibody binding to differentiating CG-4 oligodendrocytes. *Glycobiology* 6:257-263.
- Schuchman EH, Miranda SR. 1997. Niemann-Pick disease: mutation update, genotype/phenotype correlations, and prospects for genetic testing. *Genet Test*. 1:13-9.
- Schwerer B, Lassmann H, Kitz K, Bernheimer H. 1986. Ganglioside GM1, a molecular target for immunological and toxic attacks: similarity of neuropathological lesions induced by ganglioside-antiserum and cholera toxin. *Acta Neuropathol (Berl)*. 72:55-61.
- Senn HJ., Orth M, Fitzke E, Wieland H, Gerok W. 1998. Gangliosides in normal human serum. Concentration, pattern and transport by lipoproteins. *Eur J Biochem* 181: 657-662.
- Skaper SD, Katoh-Semba R, Varon S. 1985. GM1 ganglioside accelerates neurite outgrowth from primary peripheral and central neurons under selected culture conditions. *Brain Res* 355:19-26.
- Sheikh KA, Sun J, Liu Y, Kawai H, Crawford TO, Proia RL, Griffin JW, Schnaar RL. 1999. Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. *Proc Natl Acad Sci U S A*. 96:7532-7.
- Siegel DA, Walkley SU. 1994. Growth of ectopic dendrites on cortical pyramidal neurons in neuronal storage diseases correlates with abnormal accumulation of GM2 ganglioside. *J Neurochem*. 62:1852-62.
- Simons BM, Malisan F, Testi R, Nicotera P, Leist M. 2002. Disialoganglioside GD3 is released by microglia and induces oligodendrocyte apoptosis. *Cell Death Differ*. 9:758-67.
- Sobel RA, Mitchell ME. 1989. Fibronectin in multiple sclerosis lesions. *Am J Pathol*. 135:161-8.
- Stults CL, Sweeley CC, Macher BA. 1989. Glycosphingolipids: structure, biological source, and properties. *Methods Enzymol*. 179:167-214.
- Sobel RA, Mitchell ME. 1989. Fibronectin in multiple sclerosis lesions. *Am J Pathol*. 135:161-8.
- Sorice M, Longo A, Garofalo T, Mattei V, Misasi R, Pavan A. 2004. Role of GM3-enriched microdomains in signal transduction regulation in T lymphocytes. *Glycoconj J*.20:63-70.
- Stevens A, Weller M, Wietholter H. 1992. CSF and serum ganglioside antibody patterns in MS. *Acta Neurol Scand*. 86:485-9.
- Sun J, Shaper NL, Itonori S, Heffer-Laue M, Sheikh KA, Schnaar RL. 2004. Myelin-associated glycoprotein (Siglec-4) expression is progressively and selectively decreased in the brains of mice lacking complex gangliosides. *Glycobiology*. 14:851-7.
- Šišková Z, Baron W, de Vries H, Hoekstra D. Fibronectin impedes "myelin" sheet directed flow in oligodendrocytes: a role for the beta 1 integrin mediated PKC signaling pathway in vesicular trafficking. *Mol Cell Neurosci*: in press.
- Tettamanti G, Bonali F, Marchesini S, Zambotti V. 1973. A new procedure for the extraction, purification and fractionation of brain gangliosides. *Biochim Biophys Acta*. 296:160-70.
- Thomas PD, Brewer GJ. 1990. Gangliosides and synaptic transmission. *Biochim Biophys Acta*. 1031:277-89.
- Ueno K, Ando S, Yu RK. 1978. Gangliosides of human, cat, and rabbit spinal cords and cord myelin. *J Lipid Res*. 19:863-71.
- Vinson M, Strijbos PJ, Rowles A, Facci L, Moore SE, Simmons DL, Walsh FS. 2001. Myelin-associated glycoprotein interacts with ganglioside GT1b. A mechanism for neurite outgrowth inhibition. *J Biol Chem*. 276:20280-5.
- Vyas AA, Schnaar RL. 2001. Brain gangliosides: functional ligands for myelin stability and the control of nerve regeneration. *Biochimie*. 83:677-82.
- Vyas AA, Patel HV, Fromholt SE., Heffer-Laue M, Vyas KA, Dang J, Schachner M, Schnaar, RL. 2002. Gangliosides are functional nerve ligands for myelin-associated glycoprotein (MAG), an inhibitor of nerve regeneration. *Proc Natl Acad Sci* 99:8412-8417.
- Wilson R, Brophy PJ. 1989. Role of oligodendrocytes cytoskeleton in myelination. *J Neurosci Res* 22:439-448.
- Yang, LJS, Zeller CB, Shaper NL, Kiso M, Hasegawa A, Shapiro RE, Schnaar RL. 1996. Gangliosides are neuronal ligands for myelin-associated glycoprotein. *Proc Natl. Acad. Sci*. 93: 814-818.
- Yamashita T, Wu YP, Sandhoff R, Werth N, Mizukami H, Ellis JM, Dupree JL, Geyer R, Sandhoff k, Proia RL. 2005. Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glia interactions. *Proc. Natl. Acad. Sci*. 102: 2725-2730.
- Yim SH, Yavin E, Hammer JA, Quarles RH. 1991. Exogenous GM3 ganglioside stimulates process formation and glycoprotein release by cultured bovine oligodendrocytes. *J Neurochem*. 57:2144-7.
- Yim SH, Farrer RG, Hammer JA, Yavin E, Quarles RH. 1994. Differentiation of oligodendrocytes cultured from developing rat brain is enhanced by exogenous GM3 ganglioside. *J Neurosci Res* 38:268-81.

Yu RK, Ledeen RW, Eng LF. 1974. Ganglioside abnormalities in multiple sclerosis. *J Neurochem.* 23:169-174.

Zaprianova E, Deleva D, Filchev A. 1998. Ganglioside changes in brain in chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat. *Neurochem Res.* 23:1421-5.





